IL2 and neoplasm: We hypothesized that a tumor associated antigen and CD3-targeting bispecific antibody, rather than targeting to only γδ TCR, would enhance the anti-tumor effects of the transfused Vγ2Vδ2 T cells even without administration of phosphoantiens and IL2 into the animals.